1,089 results on '"Lotan, Tamara"'
Search Results
2. Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer
3. Associations between Etiologic or Prognostic Tumor Tissue Markers and Neighborhood Contextual Factors in Male Health Professionals Diagnosed with Prostate Cancer.
4. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes
5. Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer
6. Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
7. Regarding NF2 (Merlin) Status in Mesothelioma of Uncertain Malignant Potential (MUMP) or Complex Mesothelial Tumor of the Tunica Vaginalis
8. Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.
9. TFE3-Rearranged PEComa/PEComa-like Neoplasms: Report of 25 New Cases Expanding the Clinicopathologic Spectrum and Highlighting its Association With Prior Exposure to Chemotherapy
10. High-Grade, Nonsarcomatoid Chromophobe Renal Cell Carcinoma: A Series of 22 Cases With Novel Molecular Features on a Subset
11. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial
12. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
13. High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments
14. Predicting Prostate Cancer Molecular Subtype With Deep Learning on Histopathologic Images
15. “Oncocytoid Renal Cell Carcinomas After Neuroblastoma” Represent TSC-mutated Eosinophilic Solid and Cystic Renal Cell Carcinomas: Association With Prior Childhood Malignancy and Multifocality With Therapeutic Implications
16. Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others
17. ERG Status at the Margin Is Associated With Biochemical Recurrence After Radical Prostatectomy With Positive Surgical Margins
18. High-grade prostatic intraepithelial neoplasia with adjacent atypical glands
19. Sclerosing lipogranuloma
20. Metanephric stromal tumor
21. Choriocarcinoma
22. Atypical glands suspicious for prostatic carcinoma
23. Prostatic xanthoma
24. Renal papillary necrosis
25. Papillary urothelial neoplasm of low malignant potential
26. Prostatic infarct
27. Zoon balanitis
28. Interstitial cystitis/painful bladder syndrome
29. Contributors
30. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers
31. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer
32. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.
33. Collagen VI Deposition Mediates Stromal T cell Trapping through Inhibition of T cell motility in the Prostate Tumor Microenvironment
34. Validation of a digital pathology-based multimodal artificial intelligence model in oligometastatic castration-sensitive prostate cancer, including in patients from the STOMP and ORIOLE phase II randomized clinical trials.
35. A phase 2 randomized trial of neoadjuvant enoblituzumab versus standard of care in men with high-risk localized prostate cancer: The help elucidate and attack longitudinally (HEAT) prostate cancer randomized study.
36. PD13-08 ERG STATUS IN MRI VISIBLE TUMORS PREDICTS GRADE RECLASSIFICATION IN ACTIVE SURVEILLANCE
37. Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate resistant prostate cancer
38. Supplementary Figure 2 from Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images
39. Supplementary Figure 1 from Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images
40. Supplementary Tables 1 and 2 from Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images
41. Data from Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:ERG Fusion Status in Prostate Cancer Using Whole Slide Images
42. Prostate Cancer, Version 3.2024
43. A transcriptomic model for homologous recombination deficiency in prostate cancer
44. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics
45. Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer
46. An mTORC1-mediated negative feedback loop constrains amino acid-induced FLCN-Rag activation in renal cells with TSC2 loss
47. TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.
48. Epigenome‐wide association study of prostate cancer in African American men identified differentially methylated genes.
49. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy
50. Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.